Abstract: Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat, cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsaturated-saturated type.

Abstract: The current invention describes processes for obtaining of concentrates of esters of eicosapentaenoic acid and docosahexaenoic acid for their use in massive and regular human consumption either as a pharmaceutical ingredient or as a food ingredient, which are characterized by having neutral and stable organoleptic properties, free of side effects, which are typical from marine oils derivatives, and with low content of Persistent Organic Pollutants (POP).

Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.

Abstract: A process for extracting lipids from microalgae; the process involves pretreating a quantity of non-homogenized microalgae with an aliphatic alcohol for a predetermined period of time. The pretreatment liberates a substantial portion of lipids from the microalgae without requiring energy intensive cell membrane disruptive technologies. The liberated lipids are then treated with a transesterification reagent to form fatty acid methyl esters. The fatty acid methyl esters are separated from the resulting mixture and may be further purified to remove remaining solvents or other impurities. The fatty acid methyl esters produced by the process are suitable as a green energy biodiesel product.

Abstract: This invention relates to krill oil and a method for manufacturing the same. The method comprises preparing krill, adding protease to the krill and performing enzyme reaction, extracting eicosapentaenoic acid, docosahexaenoic acid, phospholipids, and astaxanthin from the krill after performing the enzyme reaction, and mixing the extracted eicosapentaenoic acid, docosahexaenoic acid, phospholipids, and astaxanthin. The protease may comprise one or more chosen from serine alkaline proteases and metallo neutral proteases. The serine alkaline proteases may comprise proteases separated from Bacillus licheniformis and the metallo neutral proteases may comprise proteases separated from Bacillus subtillis and Bacillus amyloliquefaciens.

Abstract: Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein.

Abstract: The present disclosure provides methods and compositions for the disruption of biofilms produced by Mycobacterium. Methods and compositions related to the prevention and treatment of Mycobacterium infections in which biofilm formation is implicated are also provided.

Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.

Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.

Abstract: An inbred corn line, designated BB93, is disclosed. The invention relates to the seeds of inbred corn line BB93, to the plants and plant parts of inbred corn line BB93 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line BB93 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line BB93 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line BB93.

Abstract: An inbred corn line, designated BC115, is disclosed. The invention relates to the seeds of inbred corn line BC115, to the plants and plant parts of inbred corn line BC115 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line BC115 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line BC115 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line BC115.

Abstract: An inbred corn line, designated ML12, is disclosed. The invention relates to the seeds of inbred corn line ML12, to the plants and plant parts of inbred corn line ML12 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line ML12 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line ML12 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line ML12.

Abstract: An inbred corn line, designated BC110, is disclosed. The invention relates to the seeds of inbred corn line BC110, to the plants and plant parts of inbred corn line BC110 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line BC110 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line BC 110 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line BC110.

Abstract: An inbred corn line, designated BB86, is disclosed. The invention relates to the seeds of inbred corn line BB86, to the plants and plant parts of inbred corn line BB86 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line BB86 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line BB86 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line BB86.

Abstract: An inbred corn line, designated LM3, is disclosed. The invention relates to the seeds of inbred corn line LM3, to the plants and plant parts of inbred corn line LM3 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line LM3 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line LM3 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line LM3.

Abstract: An inbred corn line, designated CB15, is disclosed. The invention relates to the seeds of inbred corn line CB15, to the plants and plant parts of inbred corn line CB15 and to methods for producing a corn plant, either inbred or hybrid, by crossing inbred corn line CB15 with itself or another corn line. The invention also relates to products produced from the seeds, plants, or parts thereof, of inbred corn line CB15 and/or of the hybrids produced using the inbred as a parent. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from inbred corn line CB15.

Abstract: The present invention describes methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of excess accumulation and/or production of subcutaneous fat, such as cellulite, and conditions related thereto, by topically applying compositions comprising Carnitine Palmitoyl Transferase-1 (CPT-1) modulators, optionally with other anti-lipid agents; and also describes compositions and methods for treating, preventing and improving the appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating loss of subcutaneous fat in the skin, wherein the compositions include natural plant constituents that stimulate lipid synthesis.

Abstract: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 25% eicosapentaenoic acid (EPA, an ?-3 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases and optionally comprise various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of EPA. Production host cells are claimed, as are methods for producing EPA within said host cells.

Abstract: This invention refers to a procedure for obtaining fatty acids of pharmacological and nutritional interest that comprises the steps of feeding a gas comprising CO2 into a reactor that contains a culture that comprises at least one species of microalgae capable of photosynthesis, the process of photosynthesis by the species of microalgae from the CO2 supplied, producing a biomass that contains a general formula (I) compound: extraction of the general formula (I) compound from the biomass obtained and concentration and/or purification of this compound.

Abstract: The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.

Abstract: The invention is directed to microbial oils containing omega-3 polyunsaturated fatty acids comprising docosahexaenoic acid, eicosapentaenoic acid, and optionally docosapentaenoic acid and dosage forms containing such oils.

Abstract: The disclosed subject matter relates generally to a method for modifying oil, and specifically to a process for increasing the concentration of polyunsaturated fatty acid in an oil composition.

Abstract: This disclosure concerns vegetable oils and products containing the same comprising poly-unsaturated fatty acids. In some embodiments, this disclosure concerns novel oil processing methods that retain an amount of docosahexaenoic acid (DHA) in a refined, bleached, and deodorized (RBD) oil produced from a crude oil sample comprising the amount of DHA.

Abstract: A process for purifying a lipid composition having predominantly neutral lipid components having at least one long chain polyunsaturated fatty acid is disclosed. The process employs contacting the lipid composition with a polar solvent, such as acetone, wherein the solvent is selected such that contaminants are less soluble in the solvent than is the long chain polyunsaturated fatty acid. The process is typically conducted at cooler temperatures, including about 0° C. Upon precipitation of the contaminants from the lipid composition, a separation is conducted to remove the precipitated material from the lipid composition. The long chain polyunsaturated fatty acids can include ARA, DPA, EPA, and/or DHA. The process of the present invention effectively winterizes lipid compositions, thereby reducing the tendency of such compositions to become hazy.

Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.

Abstract: The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.

Abstract: A kind of ?-glucosidase inhibitor, composing of mainly an unsaturated fatty acid composition, that acts to inhibit the decomposition of starch and disaccharides in the small intestine as well as slowing down the absorption of glucose, and thus achieving the objective of its application in preventing or treating diabetes and obesity.

Abstract: The present invention relates to a series of mixed esters of glycerin esters having two distinct alkyl groups present thereon. One is a low melting product, having a melting point of below 70° C. and the other having a melting point of above 90° C. The presence of the two different melting point groups on the glycerin results in a modification of the hardness, spredability and aesthetics of the resulting mixed ester. This ability to alter hardness and skin aesthetics makes the products of the present invention useful in personal care products ranging as additives to pigmented products to minimize syneresis, to stick products alter the hardness, shrinkability and aesthetics of the stick, to pressed powders where they act to modify the compressability of the powders to which they are added as well as the feel achieved when they are applied to the skin.

Abstract: Methods for production of highly unsaturated fatty acids by marine microorganisms, including the heterotrophic marine dinoflagellate Crypthecodinium, using low levels of chloride ion are disclosed. Specifically, methods of increasing production of highly unsaturated fatty acids by marine microorganisms while growing in low chloride media by manipulating sodium ion and potassium ion levels. The invention also relates to methods of production of highly unsaturated fatty acids by marine organisms at low pH levels, and includes methods for generation of low pH tolerant strains.

Abstract: Methods for production of highly unsaturated fatty acids by marine microorganisms, including the heterotrophic marine dinoflagellate Crypthecodinium, using low levels of chloride ion are disclosed. Specifically, methods of increasing production of highly unsaturated fatty acids by marine microorganisms while growing in low chloride media by manipulating sodium ion and potassium ion levels. The invention also relates to methods of production of highly unsaturated fatty acids by marine organisms at low pH levels, and includes methods for generation of low pH tolerant strains.

Abstract: The present invention relates to a series of mixed esters of complex esters having two distinct alkyl groups present thereon. One is a low melting product, having a melting point of below 70° C. and the other having a melting point of above. 90° C. The presence of the two different melting point groups on the polyol results in a modification of the hardness, spreadability and aesthetics of the resulting mixed ester. This ability to alter hardness and skin aesthetics makes the products of the present invention useful in personal care products ranging as additives to pigmented products to minimize syneresis, to stick products alter the hardness, shrinkability and aesthetics of the stick, to pressed powders where they act to modify the compressibility of the powders to which they are added as well as the feel achieved when they are applied to the skin.

Abstract: A method for lowering saturated fatty acid content, the method comprising concentrating polyunsaturated fatty acid using a lipase having low reactivity for the polyunsaturated fatty acid to react with a glyceride containing a polyunsaturated fatty acid; wherein the lipase reaction is performed at a temperature of not more than 25° C.

Abstract: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.

Abstract: This invention relates to a corn oil composition comprising unrefined corn oil having a free fatty acid content of less than about 5 weight percent, and methods for producing the same.

Abstract: The present invention describes a vegetable oil comprising a polyunsaturated fatty acid having at least 20 carbon atoms (LC-PUFA), which oil has (a) an anisidine value (AnV) of less than 25; (b) a peroxide value (POV) of less than 10; (c) a triglyceride content of greater than 90%; and/or (d) an Oil Stability Index (OSI) of greater than 5 hours at 80° C.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.

Abstract: The present invention relates to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucletides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.

Abstract: To provide a fat-and-oil in which the content of docosahexaenoic acid is increased. A process for producing highly unsaturated fatty acids comprising culturing a stramenopile capable of producing highly unsaturated fatty acids in a culture medium containing an inhibitor for fatty acid desaturases; fats-and-oils in which the content of highly unsaturated fatty acids, particularly docosahexaenoic acid produced by the relevant method, is increased. A method for enhancing the productivity of highly unsaturated fatty acids in stramenopiles, comprising culturing a stramenopile in a culture medium containing an inhibitor for fatty acid desaturases; stramenopiles having the enhanced productivity of highly unsaturated fatty acids, generated by the relevant method.

Abstract: This invention proposes a lanolin substitute, capable of absorbing up to at least twice its weight of water or aqueous solution or aqueous suspension. It forms true emulsions, stable over time with a capacity for water absorption superior to that of lanolin. It also possesses the known emollient, moisturizing and occlusive properties of lanolin. This substitute is usable in all the present and future areas of application of lanolin: in the cosmetics industry, dermatology, and in industrial applications (polishes, lubricants . . . ). It is obtained by hemi-synthesis from a mixture of unsaturated fatty acids, esters of unsaturated fatty acids, unsaturated hydrocarbons or unsaturated derivatives of the latter and compounds comprising or generating hydroxyl functions, such as glycerol, preferably without a catalyst and in an atmosphere devoid of oxygen. Classical thermal treatment or preferably treatment by dielectric heating.

Abstract: Omega-3 lipid compounds of the general formula (I): wherein R1 and R2 are the same or different and may be selected from a group of substituents consisting of hydrogen, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; X represents a carboxylic acid or a derivative thereof, a carboxylate, a carboxylic anhydride or a carboxamide; and Y is a C6 to C22 alkene with two or more double bonds, having E and/or Z configuration, are disclosed. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments in particular for the treatment of cardiovascular and metabolic diseases.

Abstract: Described are engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing an oil comprising greater than 50 weight percent of eicosapentaenoic acid [“EPA”], an ?-3 polyunsaturated fatty acid, measured as a weight percent of total fatty acids [“% TFAs”] and having a ratio of at least 3.1 of EPA % TFAs, to linoleic acid, measured as % TFAs. These strains over-express at least one ?9 elongase/?8 desaturase multizyme, in addition to other heterologous ?9 elongases, ?8 desaturases, ?5 desaturases, ?17 desaturases, ?12 desaturases, C16/18 elongases, and optionally over-express diacylglycerol cholinephosphotransferases, malonyl CoA synthetases and/or acyl-CoA lysophospholipid acyltransferases. The strains possess at least one peroxisome biogenesis factor protein knockout. Methods for producing EPA within said host cells, oils obtained from the cells, and products therefrom are claimed.

Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.

Abstract: The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent, a method for using the dentinal drug delivery to provide a dental treatment, and a method for identifying anti-inflammatory agents capable of diffusing through dentin.

Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.

Abstract: The present invention relates to a method for preparing an extract containing omega fatty acids from a plant containing omega fatty acids, including the following steps: drying the plant containing omega fatty acids to prepare a powder; and extracting omega fatty acids from the prepared plant powder by using supercritical carbon dioxide as a solvent at an optimum temperature and pressure, a dietary supplement and a cholesterol-lowering pharmaceutical composition containing plant-derived omega fatty acids extracted by the method, and omega fatty acids-containing plant extract containing a predetermined or greater amount of omega-3 fatty acids.

Abstract: Methods of producing concentrates of omega-3 fatty acid ethyl esters, from an ethyl ester composition comprising use of free fatty acids as co-catalysts for enzymatic synthesis of partial glycerides are provided. In some embodiments, methods of producing concentrates of ethyl-eicosapentanoate and/or ethyl-docosahexanoate from an ethyl ester composition containing the esters comprise a) adding glycerol, an immobilized enzyme catalyst, and a free fatty acid co-catalyst b) allow glyceryl ester synthesis to proceed by adjustment of temperatures, time and vacuum such that a substantial amount of partial glycerides is formed and c) separating an ethyl ester fraction enriched in ethyl eicosanoate and ethyl docosahexanoate from the glyceride mixture.

Abstract: A co-salt of a polyunsaturated fatty acid and a non-fatty acid is formed as a precipitate. The co-salt formed is free flowing and does not tend to agglomerate (cake) in storage. The resultant co-salt product will be easy to blend with other products to produce dietary supplements. These novel co-salt products may also tablet very well and may be added to current dietary supplement tablets.